We are live on ! Find out more
AICPI

ABG Innovation Capital Partners III Portfolio holdings

AUM $64.5K
1-Year Est. Return 1.01%
This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+1.01%
3 Year Est. Return
+5.56%
5 Year Est. Return
-85.52%
10 Year Est. Return
–
AUM
$1.48M
AUM Growth
+$131K
Cap. Flow
-$8K
Cap. Flow %
-0.54%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$8K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSTL icon
1
Castle Biosciences
CSTL
$1.02B
$877K 59.46%
33,626
– –
WHWK
2
Whitehawk Therapeutics
WHWK
$263M
$377K 25.56%
26,666
– –
SYBX
3
DELISTED
Synlogic
SYBX
$196K 13.29%
13,727
– –
ACGN
4
DELISTED
Aceragen Inc
ACGN
$21K 1.42%
3,312
– –
GNCA
5
DELISTED
Genocea Biosciences, Inc.
GNCA
$4K 0.27%
375,000
– –
NBRV
6
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-1,834
Closed -$8K

Similar funds

FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
SNN
Shen Neil Nanpeng $36.3K AUM 179.45% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
NA
Newport Asia San Francisco, California $2.21M AUM
IVSFI
IA Venture Strategies Fund II New York $4.08M AUM 174.71% 1-Year Est. Return
FFGM
Founders Fund Growth Management San Francisco, California $7.04M AUM 82.06% 1-Year Est. Return

ABG Innovation Capital Partners III's Q3 2022 Portfolio in Review

As of Q3 2022, ABG Innovation Capital Partners III held 6 positions worth $1.48M, up 9.7% from $1.34M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG Innovation Capital Partners III's Q3 2022 filing shows 1 closed position. The largest sale was Nabriva Therapeutics plc Ordinary Shares Ireland, an estimated $8K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ABG Innovation Capital Partners III fully exited Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2022, selling an estimated $8K.
  • ABG Innovation Capital Partners III's ten largest holdings make up 100% of its $1.48M portfolio in Q3 2022.
  • ABG Innovation Capital Partners III opened 0 new positions and closed 1 in Q3 2022.
  • ABG Innovation Capital Partners III's portfolio value rose 9.7% quarter-over-quarter to $1.48M.

Based on ABG Innovation Capital Partners III's 13F filing for Q3 2022, filed 14 Nov 2022.